Expert Interview
Reviewing the U.S. FDA Approval of YUTREPIA (Treprostinil) for PAH and PH-ILD from Liquidia Corporation
Ticker(s): LQDAA pulmonologist specializing in pulmonary hypertension with experience treating both PAH and PH-ILD. The expert should also have familiarity with inhaled prostacyclin therapies, patient adherence challenges, and experience participating in or reviewing data from the INSPIRE trial or similar registries.
YUTREPIA is the first dry-powder formulation of treprostinil approved for PAH and PH-ILD. Clinically, how does a dry-powder device compare to nebulized or parenteral delivery in terms of ease of use, patient adherence, and quality of life?
Added By: slingshot_insightsThe pivotal INSPIRE study included patients both naïve to treprostinil and those transitioning from nebulized therapy. What do these findings tell us about the titratability and real-world utility of YUTREPIA across different patient profiles?
Added By: slingshot_insightsGiven the diversity and historically limited treatment options for PH-ILD, how important is this approval for patients with diseases like IPF and CPFE, and do you expect YUTREPIA to be quickly adopted in this subgroup?
Added By: slingshot_insightsYUTREPIA’s low inspiratory effort design is positioned as an advantage for patients with limited lung capacity. In practice, how often do PAH or PH-ILD patients struggle with inhalation-based treatments, and how meaningful is this design improvement?
Added By: slingshot_insightsLiquidia currently faces a pending injunction motion from United Therapeutics. From your clinical perspective, how do legal disputes like these impact physician and patient decision-making when a newly approved therapy is introduced?
Added By: slingshot_insightsYUTREPIA uses PRINT® technology to produce uniform, lung-optimized particles. Can you explain how particle uniformity and deposition depth can influence both therapeutic effect and side effect profile in pulmonary hypertension?
Added By: slingshot_insightsAs YUTREPIA targets the same mechanism as Tyvaso but through a different device and formulation, what are the key differentiators that might influence a physician’s decision to transition a patient to this new formulation?
Added By: slingshot_insightsWith the ongoing ASCENT study and a second treprostinil formulation (L606) in the pipeline, what strategic position does Liquidia appear to be carving out in the broader PAH and PH-ILD treatment space?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.